Reuters logo
BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs
October 17, 2016 / 11:21 AM / a year ago

BRIEF-Regeneron, Teva provide update on fasinumab clinical development programs

Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc

* Regeneron and Teva provide update on fasinumab clinical development programs

* Regeneron and Teva provide update on fasinumab clinical development programs

* Regeneron Pharmaceuticals - co, Teva plan to design pivotal Phase 3 study in chronic low back pain that excludes patients with advanced osteoarthritis

* Regeneron Pharmaceuticals Inc - companies plan to submit a pivotal program plan for review with fda and other health authorities. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below